Revolutionizing Drug Development
Unlocking high-value next-gen modalities to revolutionize first- and best-in-class drug development.
Learn MoreAbout Us
Pioneering AI-driven drug design to revolutionize cancer treatment and improve patient outcomes
Our Mission
At Roadrunner Therapeutics, we're at the forefront of AI-driven drug design, chemistry, and oncology. Our mission is to develop breakthrough medicines that overcome drug resistance and target previously undruggable proteins.
With a world-class team that has a proven track record of success, we're poised to transform the landscape of cancer treatment.
Our Team Has Contributed To:
$6B
Value creation
13
Clinical assets
2
FDA approved drugs
Next Generation Modalities
Leveraging cutting-edge technologies to develop revolutionary precision oncology treatments
Targeted Protein Degraders
Innovative molecules that selectively degrade disease-causing proteins, offering a new paradigm in drug development.
Defeats drug resistant cancers
Degrader Antibody Conjugates (DACs)
Combining the selectivity of ADCs with the catalytic activity of degraders for enhanced efficacy and reduced side effects.
Improved efficacy and tolerability
Drugging Undruggable Targets
Leveraging synthetic lethality and ADCs to precisely target cancer cells with minimal impact on healthy tissue.
Defeats drug resistant cancers
Changing Lives
Precision medicine for maximum patient impact: Transforming cancer treatment one breakthrough at a time
Targeted Therapies
Our AI-driven approach allows us to develop highly targeted therapies, minimizing side effects and maximizing efficacy for patients with difficult-to-treat cancers.
Overcoming Resistance
By focusing on undruggable targets and novel mechanisms, we're developing treatments that can overcome drug resistance, offering hope to patients who have exhausted other options.
Accelerating Discovery
Our AI platform significantly accelerates the drug discovery process, potentially bringing life-saving treatments to patients years faster than traditional methods.
Pipeline
Transforming the treatment landscape for refractory cancers with our innovative pipeline
| Program | Indication | Preclinical | IND-Enabling | Phase 1 |
|---|---|---|---|---|
| RR-101 | Bispecific ADC Solid tumors | |||
| RR-201 | Bispecific ADC Solid tumors | |||
| RR-301 | Bispecific ADC Solid tumors | |||
| RR-401 | Bispecific ADC Solid tumors |
Multiple Programs
Diverse pipeline targeting multiple cancer types
Next-Gen Modalities
Degraders, DACs, and bispecific approaches
2026
Projected year for first IND filing
Accelerated Development Timeline
12 Months
Average time from program initiation to candidate selection, significantly faster than industry standard
Get in Touch
Interested in learning more or collaborating with us? Contact us to explore how Roadrunner Therapeutics can help advance the future of cancer treatment.
Get in Touch